S. Swann

发表

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

A. Hauschild, C. Blank, W. Miller, 2012, The Lancet.

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

S. Swann, R. Amado, A. Suttle, 2014, British Journal of Cancer.

1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM).

A. Hauschild, C. Blank, V. Chiarion Sileni, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

O-035 Phase III trial of concurrent chemotherapy and radiotherapy(CT/RT) vs CT/RT followed by surgical resection for stage IIIa(pN2)non-small cell lung cancer (NSCLC): Outcomes and implications for surgical management in North American Intergroup 0139 (RTOG 9309)

V. Rusch, R. Livingston, F. Shepherd, 2005 .

Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients

S. Swann, J. Dekker, R. Amado, 2014, British Journal of Cancer.

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

S. Swann, R. Amado, A. Suttle, 2014, British Journal of Cancer.

Phase I study of irinotecan (Ir) and cisplatin (DDP) in combination with thoracic radiotherapy (RT), either twice daily (45 Gy) or once daily (70 Gy), in patients with limited (Ltd) small cell lung carcinoma (SCLC): Early analysis of RTOG 0241.

W. Curran, H. Choy, S. Swann, 2006, Journal of Clinical Oncology.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

J. Utikal, A. Hauschild, D. Schadendorf, 2015, The Lancet.

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

A. Hauschild, D. Schadendorf, P. Ascierto, 2012, The Lancet. Oncology.

Systematic Review and Indirect Treatment Comparison of Dabrafenib and Trametinib versus Other Treatments Used in Previously Untreated Metastatic Melanoma Patients

M. Casey, S. Swann, M. Amonkar, 2015 .

Characteristics of pyrexia in BRAF V 600 E / K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I / II clinical trial

K. Flaherty, J. Sosman, J. Infante, 2015 .

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.

A. Hauschild, W. Miller, P. Rutkowski, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.

K. Flaherty, J. Sosman, J. Infante, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of new treatments in radiation oncology: are they better than standard treatments?

I. Hozo, C. Gwede, B. Djulbegovic, 2005, JAMA.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Combining BRAFV600E inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma

D. Schadendorf, S. Swann, A. Roesch, 2015, Experimental dermatology.

with combined dabrafenib and trametinib in a phase 1/2 clinical trial

K. Flaherty, J. Sosman, S. Swann, 2014 .

Gender differences in pretreatment quality of life in a prospective lung cancer trial.

B. Movsas, S. Swann, F. Siddiqui, 2008, The journal of supportive oncology.

Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group

B. Djulbegovic, H. Soares, S. Swann, 2004, BMJ : British Medical Journal.

Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.

R. Komaki, B. Movsas, S. Swann, 2008, International journal of radiation oncology, biology, physics.

Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

G. Shapiro, P. LoRusso, S. Swann, 2013, Investigational New Drugs.

A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

G. Shapiro, P. LoRusso, S. Swann, 2012, Investigational New Drugs.

Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer

Hak Choy, Geoffrey Ibbott, William Straube, 2006, Acta oncologica.

Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer

D. Yankelevitz, N. Altorki, S. Swann, 2008 .

Abstract B6: A phase II study of the efficacy and safety of foretinib, a novel receptor tyrosine kinase inhibitor, given on an intermittent 5‐days‐on/9‐days‐off (5/9) schedule in patients with recurrent or metastatic squamous cell cancer of the head and neck

P. Bonate, T. Seiwert, S. Swann, 2009 .

Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study.

P. Hwu, I. Puzanov, S. Swann, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1187PA Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma

J. Wargo, R. Murthy, R. Amaria, 2017 .

P-603 Phase I results of RTOG L-0117; a phase i/II dose intensificationstudy using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC

J. Fowler, R. Govindan, H. Choy, 2005 .

A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.

R. Murthy, Douglas B. Johnson, I. Puzanov, 2018 .

The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.

K. Ang, A. Fortin, S. Swann, 2007, International journal of radiation oncology, biology, physics.

A Phase II Study of Cetuximab (C225) in Combination with Chemoradiation (CRT) in Patients (PTS) with Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC): An Interim Overall Toxicity Report of the RTOG 0324 Trial

W. Curran, H. Choy, R. Komaki, 2005 .

Higher BED is Associated with Improved Local-regional Control and Survival for NSCLC Treated with Chemoradiotherapy: An RTOG Analysis

W. Curran, R. Komaki, W. Sause, 2005 .

Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365

A. Hauschild, C. Blank, W. Miller, 2012 .

Pharmacogenetic investigation of dabrafenib efficacy in a meta-analysis of three melanoma studies.

K. King, Judong Shen, S. Swann, 2014 .

Abstract 5652: Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma

J. Wargo, R. Murthy, R. Amaria, 2017 .

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

A. Hauschild, C. Blank, W. Miller, 2012, The Lancet.

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

A. Hauschild, D. Schadendorf, P. Ascierto, 2012, The Lancet. Oncology.

Consultation in paediatric rehabilitation for behaviour problems in young children with cerebral palsy and/or developmental delay

S. Swann, H. Wright, S. McDermott, 2002, Pediatric rehabilitation.

Society for Melanoma Research 2012 Congress

Goodman, Á., L. Cannon-Albright, 2013 .